Pfizer bets big on immuno-oncology combos with Merck KGaA

Pfizer Inc. (NYSE:PFE) is betting it can jump to frontrunner status with combination immunotherapies for cancer on the back of Monday's agreement to co-develop and co-commercialize its portfolio of immuno-oncology assets with Merck KGaA (Xetra:MRK).

Pfizer will pay $850 million up front, plus

Read the full 434 word article

How to gain access

Continue reading with a
two-week free trial.